A prospective analysis of anti-desmoglein antibody profiles in patients with rheumatoid arthritis treated with thiol compounds.
暂无分享,去创建一个
W. Fujimoto | Y. Aoyama | K. Iwatsuki | K. Fujii | Takenobu Yamamoto | T. Hamada | K. Taneichi | Tetsuya Yamamoto | Y. Hisamatsu | Mikiko Takata-Michigami | T. Yamamoto
[1] M. Amagai,et al. Pathogenic epitopes of autoantibodies in pemphigus reside in the amino-terminal adhesive region of desmogleins which are unmasked by proteolytic processing of prosequence. , 2009, The Journal of investigative dermatology.
[2] Preety M. Sharma,et al. Pathogenic anti-desmoglein MAbs show variable ELISA activity because of preferential binding of mature versus proprotein isoforms of desmoglein 3. , 2009, The Journal of investigative dermatology.
[3] M. Amagai,et al. Decline of anti‐desmoglein 1 IgG ELISA scores by withdrawal of d‐penicillamine in drug‐induced pemphigus foliaceus , 2005, Clinical and experimental dermatology.
[4] V. Aoki,et al. The Role of Intramolecular Epitope Spreading in the Pathogenesis of Endemic Pemphigus Foliaceus (Fogo Selvagem) , 2003, The Journal of experimental medicine.
[5] T. Nishikawa,et al. Induction of Pemphigus Phenotype by a Mouse Monoclonal Antibody Against the Amino-Terminal Adhesive Interface of Desmoglein 3 1 , 2003, The Journal of Immunology.
[6] W. Uter,et al. Dichotomy of Autoreactive Th1 and Th2 Cell Responses to Desmoglein 3 in Patients with Pemphigus Vulgaris (PV) and Healthy Carriers of PV-Associated HLA Class II Alleles1 , 2003, The Journal of Immunology.
[7] M. Davies,et al. Carbamazepine‐induced pemphigus , 2003, Clinical and experimental dermatology.
[8] J. Fairley,et al. Isotypes and antigenic profiles of pemphigus foliaceus and pemphigus vulgaris autoantibodies. , 2002, Clinical immunology.
[9] M. Seishima,et al. Increased antibody levels to desmogleins 1 and 3 after administration of carbamazepine , 2001, Clinical and experimental dermatology.
[10] A. Ueki,et al. Antidesmoglein Autoantibodies in Silicosis Patients with No Bullous Diseases , 2001, Dermatology.
[11] R. Hoffmann,et al. The Prevalence of Antibodies against Desmoglein 1 in Endemic Pemphigus Foliaceus in Brazil , 2000 .
[12] Komai,et al. Usefulness of enzyme‐linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus , 1999, The British journal of dermatology.
[13] R. Wolf,et al. Gaining more insight into the pathomechanisms of thiol-induced acantholysis. , 1997, Medical hypotheses.
[14] S. Brenner,et al. Penicillamine-induced bullous dermatoses. , 1996, Journal of the American Academy of Dermatology.
[15] B. Dréno,et al. Long-term interferon-alpha therapy induces autoantibodies against epidermis. , 1996, Dermatology.
[16] N. Nagarwalla,et al. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[17] V. Ruocco,et al. Pemphigus and Bullous Pemphigoid due to Drugs , 1991, International journal of dermatology.
[18] J. Zone,et al. Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. , 1991, The Journal of investigative dermatology.
[19] D. Mutasim,et al. Drug-induced pemphigus. , 1993, Dermatologic clinics.
[20] A. Hood,et al. Induction of acantholysis in organ explant culture by penicillamine and captopril. , 1989, Archives of dermatology.
[21] V. Ruocco,et al. Drug-induced pemphigus. , 1998, Clinics in dermatology.
[22] K. Hashimoto,et al. Penicillamine-induced pemphigus. Immunoglobulin from this patient induces plasminogen activator synthesis by human epidermal cells in culture: mechanism for acantholysis in pemphigus. , 1984, Archives of dermatology.
[23] J. Zone,et al. Penicillamine-induced pemphigus. , 1982, JAMA.
[24] D. Silvers,et al. Penicillamine-associated pemphigus: is it really pemphigus? , 1981, Journal of the American Academy of Dermatology.